ADARx Pharmaceuticals (ADRX) vs Lakefront Biotherapeutics (LKFT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lakefront Biotherapeutics is the larger company by market cap ($1.96 billion vs $1.85 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | LKFT |
|---|---|---|
| Share price | $17.33 | $30.00 |
| Market cap | $1.85B | $1.96B |
| 1-day change | -6.73% | +2.32% |
| YTD return | — | -8.26% |
| 1-year return | — | -14.11% |
| 5-year return | — | -43.95% |
| P/E ratio (TTM) | — | 2.85 |
| EPS (TTM) | $-1.16 | $10.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.21 | $36.24 |
| 52-week low | $17.20 | $25.68 |
| Distance from 52-week high | -25.33% | -17.22% |
| Analyst consensus | — | hold |
| Avg. price target upside | — | +0.60% |
| Average volume | 1.42M | 265.76K |
| Shares outstanding | 106.80M | 65.48M |
| Employees | 100 | 196 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
ADRX vs LKFT FAQ
Which is bigger, ADARx Pharmaceuticals or Lakefront Biotherapeutics?
Lakefront Biotherapeutics (LKFT) is larger, with a market capitalization of $1.96B compared with $1.85B for ADARx Pharmaceuticals (ADRX).
Are ADARx Pharmaceuticals and Lakefront Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.